Friday, 24 April 2020

Monoclonal Antibody Therapy Market: Demand, Overview, Price, Business Opportunities, Competitive Landscape, Key Findings

Monoclonal Antibody Therapy Market Analysis
Monoclonal antibodies are laboratory-produced antibodies that are whose purpose is to serve as the substitute of natural antibodies that can enhance or repeat the immune system's attack on harmful cells. Market Research Future (MRFR) has published and released a research report about the global monoclonal antibody therapy market that estimates boost for this Monoclonal Antibody Therapy Market Size at 10.5% CAGR (Compound Average Growth Rate) between 2016 and 2022. In terms of market value, the worth of global monoclonal antibody therapy market has been estimated to be the US $ 140 bn by the end of the forecast period.

Analyzing the market structure, this report offers insights about factors affecting the market growth. Estimating the market size and forecasting the revenue, this reports covers and observes the competitive developments of market players that include mergers and acquisitions, joint ventures, new product developments, research and developments (R&D), and strategic alliances.

The major factors strengthening the growth of the global monoclonal antibody therapy market are rising health awareness, an unhealthy lifestyle lowering the immunity of consumers and increasing spending on healthcare.

The global monoclonal antibody therapy market has been segmented on the basis of application, end user, source, and lastly, region. The application-based segmentation segments this market into analytical & chemical uses, autoimmune diseases, cancer treatment, diagnostic test, hematological disorders, and others. Based on the end user, the market has been segmented into clinics, hospitals, research laboratories, and others. Regarding source, the market has been segmented into chimeric, human, humanized, recombinant, and other.

The regional segmentation of the global blood glucose test strip market segments the global market into regional markets known as The Americas (North America & South America), Europe, Asia Pacific, and the Middle East & Africa. North America is the largest regional market. In this region, the market is growing due to the presence of major manufacturers, technological advancement, and heavy research and development (R&D) with regards to the medical sector. The topmost country-specific markets in this region are USA and Canada. Many key market players are based in this region, especially in the USA. In South America, the market is smaller than North America as this region has less advanced medical facilities. The two strongest economies that can become suitable markets are Argentina and Brazil.

Europe is the second largest regional market, and it is expected to grow during the forecast period. The factors backing the growth of this market include a high density of population, established healthcare sector, high level of technological advancement that is second only to North America, and presence of many key market players. The main country-specific markets in this region are the strongest economies known as France, Germany, and the UK, followed by the remaining countries of Europe.

The Asia Pacific is another significant market as healthcare sector is developing in countries like China and India. Advanced medical facilities and rapid technological advancement are available in Japan. The rural market in countries like China and India is still untapped which due to the high density of population can be a lucrative market once tapped into. Many key market players are based in this region too. During the forecast period, the Asia Pacific region is likely to emerge as the fastest growing regional market.

The MEA region has the least market share due to poor countries, lack of awareness, lack of education, low standard of medical facilities, lack of healthcare facilities, and majority governments not considering healthcare a priority.


Monoclonal Antibody Therapy Market Key Players
The key players in the global monoclonal antibody therapy market include AbbVie Inc. (USA), Amgen Inc. (USA), Bayer AG (Germany), Biogen Inc. (USA), Bristol – Myers Squibb Company (USA), F. Hoffmann-La Roche Ltd. (Switzerland), GenScript (USA), GlaxoSmithKline PLC (UK), Johnson & Johnson (UK), Merck KGaA (Germany), Novartis AG (Switzerland), Pfizer Inc. (USA), Sanofi (France), and Sigma-Aldrich Co. LLC (USA).

Genetic Testing Market 2020 Analytical Overview, Comprehensive Analysis, Segmentation, Competitive Landscape

Genetic Testing Market Overview
The global genetic testing market was analyzed by Market Research Future (MRFR) and it was projected that an impressive CAGR of 11.50% will be attained by the market over the forecast period of 2016 to 2024. The valuation of the genetic testing market was further stated to surpass its previous valuation and reach USD 22,834.19 Million by 2024.

The increasing prevalence of genetic-based diseases and disorders across the globe and an ongoing shift from service-driven to product-driven industry are primarily aiding the growth of the global market of genetic testing. The wide array of benefits provided by these form of tests have prompted people to take notice and be more aware of the same. This has, in turn, increased its popularity and enable people to be intrigued to go for tests in order to grab a fair understanding about their genetic structure and any possible disorders that may go through in the near future. The growing awareness about this technology has positively impacted the market and is slated to continue in the long run. However, needless to say, the high pricing associated with these tests and threat of inaccurate results can pose to be a major challenge for the market to grow and flourish.

Genetic Testing Market Segmentation
The global genetic testing market has been segmented in terms of type, method, and application.
By type, the market includes direct to consumer genetic testing and prescribed genetic testing.
By method, the market segments into chromosomal genetic tests, molecular genetic tests/ DNA tests, and biochemical, genetic tests.
By application, the market comprises predictive and pre-symptomatic testing, reproductive health, cancer screening, ancestry, and others. The reproductive health segment, which held a valuation of USD 3,993.67 million in 2018, is further narrowed into prenatal screening, carrier screening, and newborn screening. The cancer screening segment, on the other hand, was segmented into breast cancer, hereditary cancer, ovarian cancer, colon cancer, and others.
Genetic Testing Market Regional Analysis

The global genetic testing market is geographically distributed across the following key regions: Asia Pacific, North America, Europe, and the Rest of the World (RoW).

The Americas leads the global genetic testing market and is projected to continue its lead in the coming years. The presence of an established infrastructure, rising incidences of genetic diseases and abnormalities, and favorable support from the government for R&D activities to be conducted in genetics are all pushing the growth of the regional market.

The European region, standing second in the global rankings, is expected to move at a gradual pace to retain its positioning. Herein, recent developments and advancements made in molecular medicines are expected to be the vital factors influencing the market growth. Rising prevalence of genetic-related diseases in Europe has boosted the scope of development and usage of genetic tests in this region, thereby driving the market.

Asia Pacific is anticipated to be the fastest-growing regional market for genetic testing. The presence of a large pool of patient population, opportunities of potential developing in genetic testing, and fast-paced advancement in technology are cumulatively expected to push the Asia Pacific market in the coming years.

The Middle East & Africa region stands at the bottom of the pecking order in the genetic testing market standings. However, the regional market is primed for growth over the forecast period due to the increasing population of aged people, major innovations being made in genetic testing, and a rising number of chronic disease cases being reported.


Genetic Testing Market Competitive Landscape
The global genetic testing market comprises a host of key players. This includes names like Abbott Laboratories (US), PerkinElmer Inc. (US), Quest Diagnostics Incorporated (US), Bio-Rad Laboratories, Inc. (US), Myriad Genetics, Inc. (US), Illumina Inc. (US), F. Hoffmann-La Roche Ltd (Switzerland), QIAGEN (Germany), Eurofins Scientific (US), BGI Genomics (China). Blueprint Genetics (Finland), Thermo Fisher Scientific Inc. (US), and others.

Wednesday, 22 April 2020

Cardiac Pacemaker Market Emerging Technologies, Developments, Future Plans And Comprehensive Research Study

Cardiac Pacemaker Market Overview:
Cardiac pacemaker is a device that can manage the heart rhythm artificially. The device sends electric pulse to heart to keep the rhythm normal. Technological progress and curbed costs are major driving factor for the global cardiac pacemaker market, which is expected to garner 7.9% CAGR during the forecast period (2017-2023). Market research Future (MRFR) makes a claim in their recently published analysis of the global cardiac pacemaker market that the attainment of the valuation mark would be easier for the market during the forecast period.

Several factors like growing geriatric population, better affordability, technologically-advanced devices, growing health-related issues, and others are expected to help the global cardiac pacemaker market make the leap in terms of growth during the forecast period. However, the market growth can be hampered due to the necessity of surgery for the procedure, which a lot of people wish to avoid. Also, the risk of malfunctioning can be a great deterrent for the market.

Cardiac Pacemaker Market Segmentation:
MRFR’s report on the global cardiac pacemaker market has a sound foundation on segments like type, technology, application, and end-users. This segmentation is amply backed by various volume-wise and value-wise data results.
Based on the type, the cardiac pacemaker market can be segmented into external cardiac pacemaker, implantable, and others. the implantable pacemakers are expected to gain substantial market coverage.

Based on the technology, the cardiac pacemaker market can be segmented into single-chambered, biventricular, dual-chambered, and others.

Based on the application, the cardiac pacemaker market can be segmented into congestive heart failure, arrhythmias, and others. The arrhythmias segment covers tachycardia, bradycardia, and others for a better analysis.
By end-users, the cardiac pacemaker market can be segmented into medical institutes, cardiac care centers, hospitals, and others. the hospitals segment is getting traction due to patients showing high preference for this one. Hospitals are better-equipped to tackle various other aspects as well.

Cardiac Pacemaker Market Regional Analysis:
The Americas, Europe, Asia Pacific (APAC), and the Middle East & Africa (MEA) are regions that have been included in the global cardiac pacemaker market report, conducted by MRFR. This report aims at providing a closer look of the market that would help in the identification of various factors.

The Americas is enjoying the dominance it has over the global market and is expected to continue in the coming years as well by providing substantial backups for the sector. The regional market is enjoying the presence of various factors like robust infrastructure, high technological inclusion, better investment capacity, and others. The rise in geriatric population is also expected to build up market expansion possibility. 

Europe holds the second spot and is enjoying similar features like that of the Americas, especially, North America. The regional market has several countries like Germany, France, the UK, and others who are impacting the regional market. The region is also investing much for research and development, which is creating enough scope for market expansion. 

The APAC market has several regions like India, China, Australia, Japan, Korea, Thailand, Singapore, and others who are spending substantial money in taking the regional market ahead. The region is also the fastest growing one that can bank on rising healthcare expenditure, huge patient population, better per capita income, and transforming policies to ease the integration process of the global market can make the market grow faster. 


Cardiac Pacemaker Market Competitive Landscape:
Several companies are promoting the global cardiac pacemaker market substantially to take advantage from the rapidly inflating profits. These companies are launching their own strategies to solidify their market position and their efforts can ensure a holistic growth for the global cardiac pacemaker market. These companies are Abbott. (U.S.), Medtronic (U.S.), BIOTRONIK (Germany), Boston Scientific Corporation (U.S.), SORIN Group (Europe), LEPU MEDICAL (U.K), OSCOR Inc. (U.S.), MEDICO S.p.A. (Europe), and others. MRFR enlisted these companies in the recently published report on the same and had profiled them to get a detailed look into the market.

Nutraceutical Excipients Market 2020 Share, Comprehensive Research Study, Emerging Technologies and Potential Of Industry

Nutraceutical Excipients Market Overview:
Global Nutraceutical Excipients Market can take a leap from a valuation of USD 3.1 Bn in 2017 and reach USD 4.81 Bn by the end of 2023. The time frame, 2018 to 2023, can be considered as the forecast period. Market Research Future (MRFR) makes a strong statement by showing factors that can inspire better growth for the market
Hike in investment related to healthcare, transforming lifestyle triggering various diseases, and others are major factors that can significantly inspire the growth rate of the market. The growing awareness among people regarding health benefits, an increasing number of products entering the pipeline, and others can inspire the growth of the market. On the other hand, stringent regulations can hold back the growth rate in the coming years. But the market can bank on the developing technologies for better growth assistance.

Nutraceutical Excipients Market Segmentation:
The global market for nutraceutical excipients is set to find a segmentation in the report that would be based on form, function, type, and application. These segments have a better acceptance of various factors that can be taken into consideration to understand how the market can chart the future path.

By function, the market for nutraceutical excipients can be segmented into fillers, diluents & bulking agents, disintegrants, binders, lubricants, sweeteners, coating agents, and colors & flavors. The fillers, diluents & bulking agents have a chance to expand at 8.34% CAGR during the forecast period.

By form, the market for nutraceutical excipients can be segmented into liquid and dry. The former has a better market share. It has a coverage of almost 55% of the global market. It had a market valuation of USD 1 Bn in 2017. The dry segment can score a 7.34% CAGR during the review period.

By application, the market for nutraceutical excipients can be segmented into omega-3 fatty acids, proteins & amino acids, probiotics & prebiotics, and vitamins & minerals. The probiotics & prebiotics segment had the market command in 2017 when it had coverage of 47.5% market share. Its CAGR would be impressive. However, the vitamins & minerals segment has the chance for growth with a CAGR of 7.92% during the forecast period.

By type, the market report that includes nutraceutical excipients can be segmented into artificial and natural/organic. The artificial segment had better market dominance in 2018. But growing consumer awareness can inspire a better intake of the natural/organic nutraceuticals products.

Nutraceutical Excipients Market Regional Analysis:
The Americas have a high chance of contributing the maximum revenues in terms of fetching from the profit. The regional market has North and South America. North America includes the US and Canada where various global nutraceutical excipients market players are gaining hike from increasing chronic diseases, high health-related investment, better awareness, assistance from various policies, and others are expected to create better provision for the global market. Various changes in the lifestyle have influenced a hike in various diseases like diabetes, respiratory issues, and others. The market in Europe is expected to establish itself as the second-best market. Its resemblance to North America can inspire better market growth. Health cost expenditure in the region is quite high owing to which the market can witness better growth. Its intake as a preventive measure is quite high in the region.
The market in Asia-Pacific has potential as the region has several developed and fast-developing countries. For instance, markets like Australia, Japan, India, China, and South Korea can inspire the global market to register the fastest CAGR in the coming years. The market would benefit from a large number of consumers as well.


Nutraceutical Excipients Market Competitive Landscape:
A lot of companies are trying to make the market for the global nutraceutical excipients prosper with high growth opportunities. These segments are known for extensive participation in taking the market ahead. MRFR recorded their recent steps to gauge in which direction the market is moving and find better growth possibilities there. These companies are Ingredion, Cargill Corporation, Kerry, Sensient Technology Corporation, Associated British Foods plc, JRS PHARMA, Roquette Freres SA, DowDupont, Innophos, Inc., and Hilmar Ingredients.

Bioinformatics Market Trends, Global Analysis With Focus On Opportunities, Sales Revenue, Comprehensive Plans, Growth Potential

Bioinformatics Market Analysis
Global bioinformatics market is predicted to grow at a 19.8% CAGR over the forecast period (2013-2022), as per the latest Market Research Future (MRFR) report. Bioinformatics includes the integration of databases, software tools, and computers for addressing biological questions. Two vital large-scale activities which use bioinformatics include proteomics and genomics. Bioinformatics has several other applications in biology and medicine, including forensic analysis of microbes, biotechnology, drug developments, gene therapy, preventive medicines, and molecular medicines. 

Bioinformatics has proven in having extreme potential in identifying diseases beforehand, determining treatment, and helping in making human lives better. Through the knowledge and inspiration of computer science, various fields including healthcare, medicine, and gene technology can evolve by curing patients to healing the entire population. 
Various factors are propelling the bioinformatics market growth. These factors, as per the MRFR report, include increasing demand for protein sequencing and nucleic acid, initiatives from private organizations and government, and rising applications of bioinformatics. Additional factors boosting market growth include increasing need for integrated data, drug discovery, and the rising number of collaborations amongst research institutes and companies. 
On the contrary, lack of user-friendly tools at affordable prices, common data formats, and lack of skilled personnel are factors that may impede the bioinformatics market growth over the forecast period. 

Bioinformatics Market Segmentation
The Market Research Future report provides a wide segmental analysis of the bioinformatics market based on sector, services and technology, and application. 

By application, the bioinformatics market is segmented into DNA sequences, molecular phylogenetics, metabolomics, proteomics, transcriptomics, drug design, genomics, chemoinformatics, and others. Of this, the genomics segment will have the largest share in the market over the forecast period. This is owing to its rising application in preventive and personalized medicine. 

By services and technology, the bioinformatics market is segmented into sequence manipulation, data warehousing, sequence analysis, among others. 

By sector, the bioinformatics market is segmented into agriculture bioinformatics, medical bioinformatics, animal informatics, and others. Of these, the medical bioinformatics segment will dominate the market over the forecast period. This is on account of the increasing adoption of bioinformatics in clinical and pharma applications.

Bioinformatics Market Regional Analysis
Based on the region, the bioinformatics market report covers the latest trends and growth opportunities across the Asia Pacific (APAC), Europe, the Americas, and the Middle East and Africa (MEA). Of these, the Americas will remain at the forefront in the market over the forecast period. This is owing to technological advancements, rising research funding, presence of several research institutes and market players in the region, and its burgeoning demand across proteomics and genomics research. The United States and Canada are the key contributors in this region. 

The bioinformatics market in Europe is predicted to have the second-largest share over the forecast period owing to its growing demand in various end use industries. 

The bioinformatics market in the APAC region is predicted to grow at the fastest pace over the forecast period. This is owing to its rising assistance in the development of new medicines and clinical diagnostics, and increasing government initiatives to develop integrated bioinformatics systems in the region’s emerging economies.


Bioinformatics Market Key Players
Leading players profiled in the bioinformatics market report include QIAGEN, Dassault Systèmes, Thermo Fisher Scientific Inc., QIAGEN N. V, Illumina, Inc., and Agilent Technologies, among others. Key players have used various strategies to create a niche in the market such as expansions, mergers and acquisitions, partnerships, product launch and innovation, and more.

Clinical Trials Market 2023 – Size, Share, Growth, Statistics, Competitor Landscape, Key Players Analysis, Trends And Overview

Clinical Trials Market Overview
Clinical trials are medical investigations to used for research and testing purposes for the evaluation of the accuracy, efficiency, and effects of new medical treatments on human health.

According to a detailed report published by Market Research Future (MRFR), the global clinical trials market has been assessed to grow exponentially at a CAGR of 5.7% over the forecast period.

The global clinical trials market is expected to grow owing to influential factors such as the rising demand for clinical trials due to the global expansion of the healthcare sectors, increasing expenditure towards research and development of the pharmaceutical industry, growing prevalence of chronic diseases, and the focus on the treatment methods for rare diseases.

Clinical Trials Market Segmental Analysis
The global clinical trials market has been segmented based on phase, study design, indication, end users, and region.

Based on the phase, the market has been segmented into phase I, phase II, phase III, and phase IV. Among these, the phase III trial segment has been assessed to lead the market as the largest segment, owing to its high value in the healthcare sector, as well as its comparatively superior effectiveness. Phase I trial segment has been expected to grow at the fastest growth rate during the forecast period, owing to the increase in its applications in investigative new drug (IND) sector, technological advancements, and the rising government initiatives to improve the healthcare sector in emerging economies.

Based on the study design, the global clinical trials market has been segmented into expanded access interventional, and observational.

Based on indication, the global clinical trials market has been segmented into autoimmune/inflammation, cardiovascular, central nervous system (CNS) condition, diabetes, obesity, oncology, pain management, and others.
Based on the end-user, the clinical trials market is segmented into dental hospitals & clinics, dental institutes, and dental academic and research institutes.

Based on the region, the global clinical trials market has been segmented into the Americas, Europe, Asia Pacific (APAC), and the Middle East and Africa (MEA).

Clinical Trials Market Regional Analysis
The Americas have been assessed to dominate the global clinical trials market owing to the presence of multiple major pharmaceutical companies, rise in the patient population, and the increasing innovations towards product development. Additionally, the growing cases of patients suffering from chronic diseases such as cancer, diabetes, and other life-threatening diseases increases the demand for innovative drugs and contributes to the improvement of clinical trial methods to expand treatment options. These factors are also estimated to drive the clinical trials market in the region over the forecast period.

Europe has been identified as the second leading regional market for clinical trials, owing to factors such as an increase in the expenditure towards research and development in the pharmaceutical industry, and growing prevalence of chronic diseases is predictable to give a further boost to the clinical trial market. Additionally, favorable government regulations for clinical trials  further support the market growth in the region and increases the demand for new products across Europe, which will consequently lead to market growth over the forecast period.

The Asia Pacific region has been assessed as the fastest growing market  for clinical trials during the forecast period, owing to the increasing incidence of diseases, growing focus of the governments on developing medications for rare diseases and the growth in the export sector contributes substantially to the clinical trial market in the region. In countries like India, China, and Australia, the developing economy and low cost to operate clinical trial facilities supply the market growth in this region.


The Middle East & Africa has been estimated to witness slow, gradual growth in the global clinical trials market over the forecast period, owing to the presence of weak economies, lesser technical amenities, lack of medical knowledge, and limited clinical trials centers, especially in the African region decrease the market growth. The Middle East has been expected to contribute the majority of the market share in this region, due to the presence of a well-established healthcare sector and huge healthcare expenditure by the governments of countries like Saudi Arabia, Kuwait, and Qatar.


Clinical Trials Market Key players
The key players identified in the global clinical market are Charles River Laboratories, Clinipace, Eli Lilly and Company, ICON plc, Laboratory Corporation of America, Novo Nordisk A/S, Paraxel International Corporation, Pfizer, Quintiles IMS, SGS SA, among others.

Acoustic Neuroma Market 2020 Overview, Segmentation, Application, Technology, Industry Challenges, Trends And Forecast To 2023

Acoustic Neuroma Market Overview
Global acoustic neuroma market is growing pervasively, mainly due to the rising prevalence of the condition. There are several proven, effective therapeutics and devices to treat acoustic neuroma are available in the market, which is a major factor driving the growth of the Acoustic Neuroma Market. Indeed, technological advancements transpired in medical science and biotechnology is a key driving force behind the growth of the market, improving the outlook for the treatments.

According to a leading research firm - Market Research Future (MRFR), the global acoustic neuroma market is expected to garner massive accruals by 2023. In its recently published analysis, MRFR also asserts that the market would register a CAGR of approximately 7.6% throughout the forecast period (2017-2023).  Improving economic conditions are playing a pivotal role in the growth of the market, increasing the purchasing power of people, and access to quality healthcare.

Factors such as increasing per capita health care expenditures, governmental initiatives, spreading awareness towards the availability of novel treatment procedures to manage the condition are substantiating the growth of the market. Rising demand for new techniques for the diagnosis and advancements in surgical procedures fuel the growth of the market. 

Conversely, the high cost associated with the treatment & devices, alongside, the long approval time for the clinical trials are obstructing the growth of the market. Nevertheless, factors such as the large unmet needs especially in the developing regions would support the market growth over the assessment period, providing ample scope to the market to evolve further and prompting substantial investments for R&D to bring more novelty and betterments in the imaging techniques.

Global Acoustic Neuroma Market – Segments
The report is segmented into six market dynamics to widen the scope of understanding,
By Type : Unilateral Vestibular Schwannomas and Bilateral Vestibular Schwannomas.
By Diagnosis: Hearing Test (audiometry), Electronystagmography, and Magnetic Resonance Imaging (MRI), among others.
By Treatment: Monitoring, Surgery, Radiation Therapy, and Supportive Therapy, among others.
By Drug Class : Anticonvulsants, Corticosteroids, Osmotic Diuretics, and Pain Killers, among others.
By End-user : Hospitals, Diagnostic Centers, and Academic & Research Institutes, among others.
By Regions : Europe, North America, Asia Pacific, and the Rest-of-the-World.

Global Acoustic Neuroma Market – Geographical Analysis
North America dominates the global acoustic neuroma market with the largest market share. The presence of large numbers of notable players and diagnostic centers alongside, greater governmental emphasis on disease prevention & wellness foster the regional market growth. Moreover, substantial investments in R&D activities to develop novel therapies and breakthrough medicines drive the growth of the regional market.
Healthcare facilities in the US are gradually moving from treatments to wellness; as a result, the prevention and early detection of the disease become crucial. The US acoustic neuroma market, heading with the increasing diagnosed cases accounts for the largest share in the regional market. The rising prevalence of acoustic neuroma lifestyle fosters the market growth in the region.

The acoustic neuroma market in the European region is another lucrative market. Increasing numbers of cases alongside, the proliferation of advanced treatment facilities and availability of skilled medical professionals drive the market in the region. Moreover, the increasing government support for research & development, technological advancements, and well-spread awareness among people towards the availability of treatments for the condition support the regional market growth.

The Asia Pacific acoustic neuroma market is emerging as a rapidly growing market, globally. Factors substantiating the growth of the regional market include the increasing prevalence of acoustic neuroma, spreading awareness among people about the conditions, and the availability of new treatments to manage the condition. Growing markets in China and India contribute to the regional market growth majorly.

Global Acoustic Neuroma Market – Competitive Landscape
Fiercely competitive, the acoustic neuroma market appears to be fragmented due to the presence of many well-established players. These players, along with small players and new entrants, form a competitive edge in the market. To gain a competitive advantage in the market, these players incorporating strategic initiatives such as mergers & acquisitions, collaboration, expansion, and product/technology launch. Substantial investments are transpired in R&D to bring innovations in the therapy and clinical trials.


Acoustic Neuroma Market Major Players:
Players leading the global acoustic neuroma market include Siemens Healthcare (US), GE Healthcare (US), Philips Healthcare (US), Toshiba Medical Systems Corporation (Japan), Shimadzu Corporation (Japan), F. Hoffmann-La Roche AG (Switzerland), Novartis AG (Switzerland), Merck & Co., Inc. (US), and Pfizer Inc. (US), among others.

Medical Cannabis Market 2020 Analytical Overview, Comprehensive Analysis, Segmentation

Medical Cannabis Market – Overview
The use of cannabis in medical applications has risen steadily, and this development is anticipated to create a promising outlook for the medical cannabis market 2020. The healthcare industry reports are set out by Market Research Future, which centers on market choices for expansion. Medical cannabis market size is estimated to earn USD 52.35 Billion with the aid at a CAGR of 15.4%.

The rise in the occurrence of serious diseases that have the need for pain management is expected to motivate the overall medical cannabis industry in the forecast period. Moreover, the presence of appropriate outlets for the distribution of medical cannabis is expected to elevate the market development in the forecast period.

Medical Cannabis Market  Segmental Analysis
The segmental investigation of the medical cannabis market is conducted on the basis of product form, derivative, application, distribution channel, region. On the basis of product form, the medical cannabis market is segmented into solids, powders, ointments & creams, oil, others. Based on the derivative, the medical cannabis market is segmented into tetrahydrocannabinol (THC) and cannabidiol (CBD). On the basis of application, the medical cannabis market is segmented into Alzheimer’s disease, cancer, arthritis, and schizophrenia. On the basis of the distribution channels, the medical cannabis market is divided into online stores and retail pharmacy. Based on the region, the medical cannabis market is segmented into Europe, the Americas, Middle East, Asia-Pacific, and Africa.

Medical Cannabis Market  Detailed Regional Analysis 
The regional examination of the medical cannabis market includes regions such as Europe, the Americas, Middle East, Asia-Pacific, and Africa. The region in the Americas is anticipated to be the principal market due to the collective incidence of medical cannabis products and increasing per capita healthcare spending. The increasing occurrence of cancer cases has improved the development of the medical cannabis market in the Asia-Pacific, which is also expected to be the fastest-growing. The Middle East & Africa medical cannabis market is also expected to gain momentum in the duration of the forecast period.

Medical Cannabis Market  Competitive Analysis
The access to funding is expected to encourage further development of the market in the upcoming period. The aid provided by government bodies and trade bodies is forecasted to create better prospects for progress in the market globally. The enhancement in the functioning and quality of products is estimated to open up new avenues for progress in the forecast period. The instabilities in the currency are anticipated to even out and consequently generate a promising influence on the market. The contenders in the market existing in harmony with each other, and barriers to entry in the market are predicted to become less challenging in the future. The alternation in consumer trends is predicted to create a surge in a variety of products that will be offered in the market. The market is projected to create a favorable growth backdrop for companies operating in the market. The diversification of production strategies is estimated to create a positive effect on the global market. The combined effect is formed in the middle of supply and demand forces in the market is anticipated to encourage additional development of the market.

The noteworthy companies in the medical cannabis market are Maricann Inc. (Canada), Medical Marijuana, Inc. (US), Tilray (Canada), Aphria, Inc. (Canada), United Cannabis (US), GW Pharmaceuticals PLC (UK), Cannabis Sativa Inc. (US), CanniMed Ltd (Canada), Canopy Growth Corporation (Canada), MediPharm Labs (Canada), Aurora Cannabis (Canada) and GBSciences Inc. (US) to name a few.


Medical Cannabis Industry Updates:
Feb 2020 Europe’s leading independent cannabis company, EMMAC Life Sciences Group is combining pioneering science and research with pioneering extraction, cultivation, and production has recently introduced the presentation of Medican, the primary operational distance pharmacy in the UK devoted to delivering medical cannabis prescriptions.

Airway Management Market: 2020 Global Industry Share, Size, Key Players, Trends, Competitive And Regional Forecast

Airway Management Market Overview: 
The global airway management market report, as discussed in detail by Market Research Future (MRFR) in their report, discloses possibilities of the market reaching a substantial USD 1764.47 million with a 5.2% CAGR over the forecast period (2019-2025).

Airway management system relies on detailed maneuvers and medical procedures that are necessary to prevent and, if needed, relieve airway obstruction. The process tries to establish a connection between a patient's lungs and the atmosphere to provide relief. Various factors are impacting the global airway management market and MRFR tried to analyse them in their latest report. These are the rising instances of chronic obstructive pulmonary diseases, adoption of advanced technologies with substantial takers, increasing initiatives to make people and various organizations aware of the needs of these advanced systems, and surge in traffic accidents that require immediate relief. Technological advancement is playing a crucial role in deciding the future of the market as several companies are looking at it as an advantageous factor that could lift their market prospect.

However, the risk associated with dealing neonatal cases is substantial. Also, the lack in expert hands to operate such complicated devices can curb the airway management market prospect. 

Airway Management Market Segmentation:
MRFR’s take on the airway management is based on product type, application, and end user. Insights from this segmentation are expected to help proper understanding of the market.

By product type, the global airway management market can be segmented into supraglottic, anesthesia masks, laryngoscopes, accessories, infra-glottic, and others. The supraglottic segment would dominate the global market.
By application, the report on the airway management market would includes general anesthesia, surgery, respiratory care, and others.

By end user, the airway management market report can be segmented into surgical centers, hospitals, and others. In hospitals, the system is expected to gain better inclusion. 

Airway Management Market Regional Analysis: 
North America would display their strength in the market and is expected to outperform other regions in the coming years. This is primarily due to the increasing structural change in the region. Superlative infrastructure, high investment capacity, better support system in time of need, and others are expected to boost regional market setup.
The growth in Europe would follow the same trail as countries like Russia, France, Germany, the UK, and others offer the same kind of outlook like that of North American countries like the US and Canada.

In Asia Pacific, the airway management market would depend much on the emerging economies. These economies are spending to develop their healthcare sector and inspire better upgradation. Such endeavors would create scope for increased intake of airway management. 


Airway Management Market Competitive Analysis:
Various global players are showing notable interest in the airway management market to profit from its mandatory inclusions in several healthcare organizations. These companies and their strategic implementations are expected to make sure the market does not remain stagnant in the coming years. The strategic inputs include various mergers, acquisitions, new product launches, innovations in methods, and others to ensure better market strategies. These companies are Salter Labs (US), Medtronic (Ireland), Smiths Group PLC [UK] (Smiths Medical), Teleflex Incorporated (US), Sunmed (US), Vyaire Medical (US), Roper Technologies (US) (Verathon Inc.), Sourcemark (US), Ambu A/S (Denmark), Vbm Medizintechnik GmbH (Germany), Intersurgical Inc (UK), and others. 

Airway Management Industry News:
In March 2020, Pouchot Dentistry of Gloucester announced that they would launch several other services to make sure that their patients get the best-quality support. Among these extended services, proper airway management would play a dominant role. 

Biosimilars Market 2020 Size, Share, Leading Growth Drivers, Emerging Audience, Segments, Industry Sales

Biosimilars Market Synopsis
Market Research Future (MRFR) postulates that the global biosimilars market is predicted to garner USD 3.35 billion, grabbing a CAGR of 26% throughout the forecast period (2017-2023). The augmenting incidences of several chronic diseases are estimated to favor the Biosimilars Market Growth. Biosimilars are referred to as a biological medical product which are identical copies of the original medical product. They are generally derived from a plant, bacteria, yeast, and other several processes. Biosimilars are neither generics nor treated like generic drugs. Also acknowledged as bio-pharmaceuticals, biosimilars differ from generics in the manufacturing process. They are produced by two main processes, recombinant DNA technology and controlled gene expression.

Biosimilars Market Potential and Pitfalls
With the augmenting incidences of several chronic diseases, growing demand for cheap medical products, and strategic collaborations leading to clinical trials and enhanced productivity, the global biosimilars market is estimated to flourish throughout the appraisal period. Biosimilars are extensively used in the treatment and prevention of chronic diseases like cancer, diabetes, autoimmune disease, cardiovascular diseases (CVDs), kidney failure, rheumatoid arthritis, hematological disease, hormone growth deficiency, and infectious disease. This is likely to create momentum to the market growth during the estimated period. Also, with the growth in the geriatric population, the demand for biosimilars is expected to trigger.

Biosimilars are constantly gaining prominence over other conventional biologics due to lesser cost as compared to the parent biological drugs. Moreover, different private and government bodies are promoting the use of biosimilars over synthetic drugs and conventional biologics, which is further propelling the growth of the market across the globe. Also, with the rapid growth in the pharmaceutical sector combined with the high cost of existing biological drugs, the market is anticipated to boom.

On the contrary, physician skepticism coupled with the lack of awareness regarding biosimilars is some of the top barriers likely to vitiate the market growth in the coming years. Additionally, complexity and high manufacturing cost can act as roadblocks to the mainstream production of biosimilars. Despite such hiccups, discounted prices of biosimilars will impact the overall biosimilar sales, as patients are the key beneficiaries.

Global Biosimilars Market: Segmental Analysis
The global biosimilars market has been segmented on the basis of product, application, and manufacturing.
By mode of product, the global biosimilars market has been segmented into recombinant non-glycosylated proteins, recombinant glycosylated proteins, and others. Among these, the recombinant glycosylated proteins segment is anticipated to occupy the largest share and is likely to retain its dominance. The growth is credited to the wide therapeutic area of such proteins coupled with the presence biosimilar version of monoclonal antibodies at much lower rates.

By mode of application, the global biosimilars market has been segmented into oncology, immune diseases, blood-related disorders, and others.

By mode of manufacturing, the global biosimilars market has been segmented into contract manufacturing and in-house manufacturing. Among these, the in-house manufacturing is presumed to occupy the largest share owing to the rising demand for cost-effective biosimilar products due to the augmenting incidences of several chronic diseases.

Biosimilars Market Regional Insights
Geographically, the biosimilars market span across regions namely, Europe, Asia Pacific, North America, and the Middle East & Africa.

Among all the regions, the European region is likely to dominate the global biosimilars market and is estimated to retain its dominance in the coming years. The growth is credited to the rising prevalence of diseases coupled with the growth in the geriatric population in this region. Moreover, advanced medical research and technological advancements are further triggering the demand for biosimilars in this region. The growth in the regional market is likely to be stimulated by patent expiry of biologic products combined with the launch of new biosimilars and the advent of new market participants.

The North American region is predicted to occupy the second largest share in the global market owing to technological advancements and extensive medical research. The market is mainly driven by the presence of large research labs such as Amgen, Sandoz, Teva Pharmaceutical, and others.

The Asia Pacific region is anticipated to emerge as the fastest-growing region owing to the immense economic development coupled with the booming biotechnology companies in this region. The country-specific markets in this region generating maximum revenue are India, Australia, South Korea, Japan, and China.


Biosimilars Industry Updates
February 19, 2019: Sandoz, a developer of biosimilar has recently announced the launch of their biosimilar adalimumab, Hyrimoz, in Spain. This biosimilar, referencing Humira, was authorized in the European Union for sale in July 2018. It has been approved for indications of reference adalimumab and is available in 40 mg doses for subcutaneous injection in pre-filled pen or a syringe form.

Biosimilars Market Competitive Dashboard
The prominent players operating the global biosimilars market are Biocon Ltd. (India), Eli Lilly (U.S.), Novartis (Switzerland), Celltrion Inc. (South Korea), Dr. Reddy’s Laboratories Ltd. (India), Pfizer Inc. (U.S.), Teva Pharmaceuticals Industries Ltd. (Israel), Sandoz International GmbH (Germany), Astra Zeneca (U.K.), Amgen Inc. (U.S.), Samsung Bioepis (South Korea), F. Hoffmann-La Roche Ltd. (Switzerland), and Accord Healthcare (U.K.).